Hypersensitivity reactions to pertuzumab/trastuzumab fixed-dose combination (PHESGO®): successful management with a simplified 9-step subcutaneous desensitization protocol.

Mattia Cristallo, Mirco Filieri, Luigia Stefania Stucci, Nada Chaoul, Marcello Albanesi, Cataldo Piarulli, Attilio Di Girolamo

Abstract read

PubMed Publisher

In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mattia CristalloDepartment of Precision and Regenerative Medicine and Ionian Area-DiMePRe-J, Postgraduate School in Allergology and Clinical Immunology, University of Bari "A. Moro", Bari, 70124, Italy. cristallomattia@gmail.com.

Mirco FilieriDepartment of Precision and Regenerative Medicine and Ionian Area-DiMePRe-J, Postgraduate School in Allergology and Clinical Immunology, University of Bari "A. Moro", Bari, 70124, Italy.

Luigia Stefania StucciInterdisciplinary Department of Medicine, University of Bari "A. Moro" and Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, 70124, Italy.

Nada ChaoulInterdisciplinary Department of Medicine, University of Bari "A. Moro", Bari, 70124, Italy.

Marcello AlbanesiInterdisciplinary Department of Medicine, University of Bari "A. Moro", Bari, 70124, Italy.

Cataldo Piarulli"M. Albanesi" Allergy and Immunology Unit, Bari, 70124, Italy.

Attilio Di GirolamoDepartment of Precision and Regenerative Medicine and Ionian Area-DiMePRe-J, Regional Reference Center for Allergic and Immunological Diseases, Bari, 70124, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypersensitivity reactions (HSRs) to anti-HER2 monoclonal antibodies may limit access to optimal therapy in HER2-positive breast cancer. HSRs have been reported with both intravenous pertuzumab/trastuzumab and the fixed-dose subcutaneous pertuzumab/trastuzumab formulation, including severe systemic reactions and anaphylaxis, although the overall incidence is low. We describe a patient with metastatic HER2-positive breast cancer who developed an immediate hypersensitivity reaction during intravenous pertuzumab administration followed by recurrent delayed cutaneous manifestations after anti-HER2 treatment and, subsequently, after subcutaneous PHESGO® administration. Diagnostic work-up revealed selective intradermal reactivity to pertuzumab, whereas trastuzumab remained consistently negative. A CFSE-based lymphocyte proliferation assay demonstrated increased CD3

Indexed as

Drug desensitizationDrug hypersensitivityLymphocyte proliferation testMonoclonal antibodiesPertuzumabPHESGO®

Identifiers

PMID42814160

DOI10.3390/curroncol32120658

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.